Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › dexamethasone

dexamethasone

24 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of dexamethasone

448 trials tracked of dexamethasone: 163 in phase 3 or 4 and 67 with published results. The most-cited published study has 1317 citations.

448Trials tracked
163Phase 3 & 4
0Recruiting
67With published results
Phase distribution
Phase 4 51 Phase 3 112 Phase 2 232 Phase 1 22 Other / NA 31
  1. Phase 3 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Completed · 1,317 cited
  2. Phase 3 Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Completed · 419 cited
  3. Phase 3 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Completed · 400 cited
  4. Phase 3 Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 381 cited
  5. Phase 3 Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients Completed · 378 cited
  6. Phase 3 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex Completed · 324 cited
Show 44 more trials
  1. Phase 3 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Completed · 322 cited
  2. Phase 3 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed · 277 cited
  3. Phase 3 Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting Completed · 251 cited
  4. Phase 3 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 248 cited
  5. Phase 3 05-001: Treatment of Acute Lymphoblastic Leukemia in Children Completed · 238 cited
  6. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 226 cited
  7. Phase 3 Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Completed · 206 cited
  8. Phase 3 PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial Completed · 204 cited
  9. Phase 3 Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed · 170 cited
  10. Phase 3 Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma Completed · 162 cited
  11. Phase 3 Adaptive COVID-19 Treatment Trial 4 (ACTT-4) Completed · 152 cited
  12. Phase 3 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Completed · 140 cited
  13. Phase 4 Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI) Completed · 132 cited
  14. Phase 3 A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Completed · 127 cited
  15. Phase 3 Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Completed · 120 cited
  16. Phase 3 Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) Completed · 119 cited
  17. Phase 3 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Completed · 103 cited
  18. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 100 cited
  19. Phase 3 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma Completed · 97 cited
  20. Phase 4 Tumor Gene Expression in Women With Ovarian Cancer Completed · 89 cited
  21. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 84 cited
  22. Phase 4 Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty Completed · 75 cited
  23. Phase 4 Ropivacaine Block Alone or With Perineural or Systemic Dexamethasone for Pain in Shoulder Surgery Completed · 65 cited
  24. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 57 cited
  25. Phase 3 Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) Completed · 49 cited
  26. Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed · 48 cited
  27. Phase 3 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma Completed · 47 cited
  28. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 46 cited
  29. Phase 4 Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema Completed · 45 cited
  30. Phase 4 Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19 Completed · 43 cited
  31. Phase 3 A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed · 43 cited
  32. Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma Completed · 40 cited
  33. Phase 3 A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting Completed · 39 cited
  34. Phase 4 Dexamethasone for Post-cesarean Delivery Pain Completed · 37 cited
  35. Phase 3 Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 36 cited
  36. Phase 3 Corticosteroids for Children With Febrile Urinary Tract Infections Completed · 33 cited
  37. Phase 3 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. Completed · 32 cited
  38. Phase 3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed · 32 cited
  39. Phase 3 Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients Completed · 31 cited
  40. Phase 3 Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma Completed · 31 cited
  41. Phase 3 A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC Completed · 24 cited
  42. Phase 3 Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial Completed · 22 cited
  43. Phase 4 Corticosteroids for Acute Migraine in the Emergency Department Completed · 20 cited
  44. Phase 4 Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period Completed · 20 cited

Showing the 50 most-cited and recently-updated of 448 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis compares adjunctive therapies for proliferative vitreoretinopathy
Ophthalmology Meta-analysis
Network meta-analysis compares adjunctive therapies for proliferative vitreoretinopathy Oral retinoic acid shows promise for retinal detachment repair
Oral retinoic acid significantly improves retinal reattachment rates in PVR patients, with strong evidence for visual acuity and reduced com…
A study found oral retinoic acid may improve retinal reattachment rates after surgery for certain eye conditions, offering a potential new t…
Jun 1, 2026
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
Oncology FDA Approval
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
FDA May 5, 2026
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
Oncology FDA Approval
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
FDA May 2, 2026
Adding dexmedetomidine to dexamethasone does not prolong analgesia in upper limb surgery
Anesthesiology & Pain Medicine RCT
Adding dexmedetomidine to dexamethasone does not prolong analgesia in upper limb surgery Combining two drugs offered no pain relief advantage over one drug alone
This randomized, triple-blind trial in 100 patients undergoing upper limb surgery found that adding i.v.
A trial of 100 patients found that adding dexmedetomidine to dexamethasone did not extend pain relief or reduce opioid use after upper limb …
May 1, 2026
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Oncology Sys. Review
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Frontiers Apr 28, 2026
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL
Allergy & Immunology Cohort
PD-L1-armored CAR-T followed by allo-HSCT yields 7-year remission in refractory B-cell ALL New Leukemia Treatment Keeps Adult Patient Cancer Free For Seven Years
This retrospective observational analysis of a single clinical case describes an adult patient with early-relapsed, chemorefractory B-cell a…
A new dual-targeted therapy helped an adult with tough leukemia stay cancer-free for seven years after standard treatments failed.
Frontiers Apr 27, 2026
Baseline Cytokine Levels Linked to Placebo Response in Cancer Dyspnea Trial
Oncology RCT
Baseline Cytokine Levels Linked to Placebo Response in Cancer Dyspnea Trial High Inflammation Might Reduce Placebo Effect in Cancer
This exploratory analysis of an RCT in 45 cancer patients with dyspnea found a negative association between baseline cytokine levels and sym…
Scientists found that high inflammation levels may stop the placebo effect from working well.
Apr 24, 2026
EMS Bundle for Pediatric Life-Threatening Asthma Evaluated in PECARN Pilot
Allergy & Immunology Phase II
EMS Bundle for Pediatric Life-Threatening Asthma Evaluated in PECARN Pilot Early Meds Could Cut Hospital Stays for Wheezing Kids
This Phase 2 pilot trial in the Pediatric Emergency Care Applied Research Network assessed an EMS treatment bundle and checklist for childre…
Kids with severe asthma might avoid hospital stays if they get breathing meds right after the 911 call.
CT.gov Apr 24, 2026
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
Oncology Cohort
Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma New Lymphoma Therapy Helps Patients Live Longer
This retrospective cohort study of 79 Korean patients with relapsed or refractory diffuse large B-cell lymphoma evaluated tisagenlecleucel.
A new study shows a specific immune therapy can shrink tumors and extend life for lymphoma patients who have run out of options.
Frontiers Apr 24, 2026
High-dose dexamethasone during chemotherapy shows no significant cortisol changes in breast cancer
Diabetes & Endocrinology Cohort
High-dose dexamethasone during chemotherapy shows no significant cortisol changes in breast cancer Chemotherapy Steroids May Not Shut Down Your Body’s Stress System
This prospective pilot study included 47 women with breast cancer receiving paclitaxel and dexamethasone.
This small study suggests that the body’s natural ability to make stress hormones might stay intact during certain chemotherapy regimens, ea…
Frontiers Apr 23, 2026
High-volume PENG block with dexamethasone showed no analgesic advantage over conventional volume in primary total hip arthroplasty
Anesthesiology & Pain Medicine RCT
High-volume PENG block with dexamethasone showed no analgesic advantage over conventional volume in primary total hip arthroplasty More Numbing Fluid Does Not Mean Less Pain
This randomized, controlled trial enrolled 40 patients undergoing primary total hip arthroplasty under spinal anesthesia.
Giving doctors more numbing medicine around the hip nerve does not help patients feel less pain after surgery.
Apr 18, 2026

All dexamethasone Articles